FDA Adverse Event Injury Summary report: N

SMARTSET GHV GENTAMICIN 40G

MDR report key: 9202128 · Received October 17, 2019

Report

Report Number
1818910-2019-110332
Event Type
Injury
Date Received
October 17, 2019
Date of Event
December 4, 2018
Report Date
September 24, 2019
Manufacturer
DEPUY CMW - 9610921
Product Code
LOD
UDI-DI
10603295174288
PMA / PMN Number
K033563
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
TX, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

PRODUCT COMPLAINT # (B)(4). MFR#1818910-2019-110332 IS BEING RETRACTED SINCE IT WAS FOUND TO BE A DUPLICATE OF MFR# 1818910-2019-79537. MFR#1818910-2019-79537 WILL BE KEPT FOR INVESTIGATION PURPOSES

Additional Manufacturer Narrative · 1

(B)(4). INITIAL REPORTER OCCUPATION: LAWYER. IF INFORMATION IS OBTAINED THAT WAS NOT AVAILABLE FOR THE INITIAL MEDWATCH, A FOLLOW-UP MEDWATCH WILL BE FILED AS APPROPRIATE.

Description of Event or Problem · 1

MEDICAL RECORDS RECEIVED 17 JUNE 2019 AND WERE REVIEWED 24 SEPTEMBER 2019 FOR MDR REPORTABILITY. ON (B)(6) 2014, THE PATIENT UNDERWENT TOTAL RIGHT KNEE ARTHROPLASTY DUE TO OSTEOARTHRITIS. THE PATELLA WAS RESURFACED. THE SURGEON REPORTED NO INTRAOPERATIVE COMPLICATIONS. THE PATIENT WAS IMPLANTED WITH THE ATTUNE KNEE SYSTEM AND SMARTSET BONE CEMENT X 2. ON (B)(6) 2018, THE PATIENT UNDERWENT A RIGHT KNEE REVISION DUE TO LOOSENING OF THE TIBIAL COMPONENT, AND PAIN. THE SURGEON INDICATED THE TIBIAL COMPONENT WAS LOOSE WITH NO CEMENT ADHERING TO THE IMPLANT. HE NOTED THE FEMORAL COMPONENT WAS NOT LOOSE AND WAS NOT REVISED. THE SURGEON INDICATED THE PATELLAR COMPONENT WAS STABLE AND NOT REVISED. THE PATIENT WAS IMPLANTED WITH A COMPETITOR¿S TIBIAL COMPONENTS AND CEMENT. THERE WERE NO COMPLICATIONS TO THE PROCEDURE. DOI: (B)(6) 2014; DOR: (B)(6) 2018; (RT KNEE).

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
996675 SMARTSET GHV GENTAMICIN 40G BONE CEMENT : BONE CEMENT LOD DEPUY CMW - 9610921 7786750 10603295174288

Patients

Seq Age Sex Outcome Treatment
1 64 YR Required Intervention